company background image
STOK

Stoke TherapeuticsNasdaqGS:STOK Stock Report

Market Cap

US$883.4m

7D

7.3%

1Y

-38.2%

Updated

14 Oct, 2021

Data

Company Financials +
STOK fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

STOK Overview

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States.

Stoke Therapeutics Competitors

Moderna

NasdaqGS:MRNA

US$134.0b

Alnylam Pharmaceuticals

NasdaqGS:ALNY

US$24.9b

BioMarin Pharmaceutical

NasdaqGS:BMRN

US$14.2b

Sarepta Therapeutics

NasdaqGS:SRPT

US$7.1b

Price History & Performance

Summary of all time highs, changes and price drops for Stoke Therapeutics
Historical stock prices
Current Share PriceUS$24.04
52 Week HighUS$21.42
52 Week LowUS$71.58
Beta0.29
1 Month Change0.46%
3 Month Change-27.92%
1 Year Change-38.25%
3 Year Changen/a
5 Year Changen/a
Change since IPO-5.98%

Recent News & Updates

Sep 30
We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate

We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Shareholder Returns

STOKUS BiotechsUS Market
7D7.3%1.0%1.1%
1Y-38.2%14.0%26.8%

Return vs Industry: STOK underperformed the US Biotechs industry which returned 10.6% over the past year.

Return vs Market: STOK underperformed the US Market which returned 24.8% over the past year.

Price Volatility

Is STOK's price volatile compared to industry and market?
STOK volatility
STOK Beta0.29
Industry Beta0.98
Market Beta1

Stable Share Price: STOK is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: STOK's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201479Ed Kayehttps://www.stoketherapeutics.com

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary ribonucleic acid therapeutics platform, Targeted Augmentation of Nuclear Gene Output (TANGO), to design ASOs to upregulate the expression of protein by individual genes in a patient. Its lead product candidate is STK-001 that is used to treat Dravet syndrome, a severe and progressive genetic epilepsy.

Stoke Therapeutics Fundamentals Summary

How do Stoke Therapeutics's earnings and revenue compare to its market cap?
STOK fundamental statistics
Market CapUS$883.45m
Earnings (TTM)-US$67.00m
Revenue (TTM)n/a

0x

P/S Ratio

-13.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
STOK income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
ExpensesUS$67.01m
Earnings-US$67.00m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-1.82
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did STOK perform over the long term?

See historical performance and comparison

Valuation

Is Stoke Therapeutics undervalued compared to its fair value and its price relative to the market?

3.46x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate STOK's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate STOK's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: STOK is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: STOK is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate STOK's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: STOK is overvalued based on its PB Ratio (3.5x) compared to the US Biotechs industry average (2.9x).


Future Growth

How is Stoke Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

-14.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: STOK is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: STOK is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: STOK is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: STOK is forecast to have no revenue next year.

High Growth Revenue: STOK is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: STOK is forecast to be unprofitable in 3 years.


Past Performance

How has Stoke Therapeutics performed over the past 5 years?

-52.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: STOK is currently unprofitable.

Growing Profit Margin: STOK is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: STOK is unprofitable, and losses have increased over the past 5 years at a rate of 52.8% per year.

Accelerating Growth: Unable to compare STOK's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: STOK is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).


Return on Equity

High ROE: STOK has a negative Return on Equity (-26.27%), as it is currently unprofitable.


Financial Health

How is Stoke Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: STOK's short term assets ($260.2M) exceed its short term liabilities ($8.2M).

Long Term Liabilities: STOK's short term assets ($260.2M) exceed its long term liabilities ($1.2M).


Debt to Equity History and Analysis

Debt Level: STOK is debt free.

Reducing Debt: STOK has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: STOK has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: STOK has sufficient cash runway for 2.4 years if free cash flow continues to reduce at historical rates of 49.1% each year.


Dividend

What is Stoke Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate STOK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate STOK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if STOK's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if STOK's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of STOK's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure


CEO

Ed Kaye (72 yo)

4yrs

Tenure

US$4,947,296

Compensation

Dr. Edward M. Kaye, also known as Ed, M.D., Ph.D. has been Special Regulatory and Scientific Advisor of Sarepta Therapeutics, Inc. since June 28, 2017. He serves as Independent Director at Avidity Bioscien...


CEO Compensation Analysis

Compensation vs Market: Ed's total compensation ($USD4.95M) is above average for companies of similar size in the US market ($USD2.28M).

Compensation vs Earnings: Ed's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: STOK's management team is considered experienced (2.3 years average tenure).


Board Members

Experienced Board: STOK's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.6%.


Top Shareholders

Company Information

Stoke Therapeutics, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Stoke Therapeutics, Inc.
  • Ticker: STOK
  • Exchange: NasdaqGS
  • Founded: 2014
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$883.448m
  • Shares outstanding: 36.75m
  • Website: https://www.stoketherapeutics.com

Number of Employees


Location

  • Stoke Therapeutics, Inc.
  • 45 Wiggins Avenue
  • Bedford
  • Massachusetts
  • 1730
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/14 22:45
End of Day Share Price2021/10/14 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.